Skip to content

Effects of Inhaled Bicarbonate on Airway pH in Cystic Fibrosis

Effects of Inhaled Bicarbonate on Airway pH in Cystic Fibrosis

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03391414
Enrollment
12
Registered
2018-01-05
Start date
2014-08-31
Completion date
2016-07-31
Last updated
2018-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic Fibrosis

Keywords

thick mucus, obstructive lung disease

Brief summary

This study will compare the use of inhaled concentrated sodium chloride solution to an inhaled solution of sodium bicarbonate in an attempt to decrease the thickness and stickiness of the mucus in the lungs of a person with cystic fibrosis. Also, this study is also looking at whether or not it is possible to decrease the acidity of the airways by inhaling sodium bicarbonate through nebulizer treatments.

Detailed description

This study will compare the use of inhaled concentrated sodium chloride solution to an inhaled solution of sodium bicarbonate in an attempt to decrease the thickness and stickiness of the mucus in the lungs of a person with cystic fibrosis. Also, this study is also looking at whether or not it is possible to decrease the acidity of the airways by inhaling sodium bicarbonate through nebulizer treatments.

Interventions

DRUGhypertonic bicarbonate

8.4% sodium bicarbonate inhaled

DRUGsodium chloride

7% sodium chloride inhaled

Sponsors

Cystic Fibrosis Foundation
CollaboratorOTHER
Joseph Pilewski
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. FEV1 greater than 50% predicted. 2. Ability to spontaneously expectorate sputum (with or without chest physiotherapy). 3. Stable disease as defined by absence of

Exclusion criteria

numbers 3-5 and clinician assessment.

Design outcomes

Primary

MeasureTime frameDescription
Exhaled breath condensate pH changetwo time points (baseline and four (4) hours)Change in pH after inhalation of two doses on one day

Secondary

MeasureTime frameDescription
Expectorated sputum changetwo time points (Baseline and four (4) hours)Change in sputum wet-to-dry ratio ratio after inhalation of two doses on one day
Spirometrytwo time points (baseline and four (4) hours)FEV1 before and after inhalation of two doses on one day

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026